Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of subcutaneous DR10624 in severe hypertriglyceridemia
CTR20242453Phase 2Completed
- Sponsor
- Zhejiang Daer Biotechnology
- Start
- Jul 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of DR10624 in hypertriglyceridemia, sponsored by Zhejiang Daer Biotechnology. Started Jul 2024; status: completed.
02
Drugs
DR10624
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on CTR20242453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242453.